Hims & Hers debates ‘unresolved’ after earnings, says Morgan Stanley
Morgan Stanley notes that Hims & Hers beat in Q4 and guided Q1 and calendar year 2025 revenue significantly above the Street consensus.
Hims & Hers Stock Tumbles Despite Beating Expectations
Hims & Hers Health shares tumbled despite the telehealth provider beating fourth-quarter expectations and offering ...
Morgan Stanley downgrades Hims & Hers on valuation concerns
Morgan Stanley downgraded Hims Hers Health Inc (NYSE:HIMS) to "Equal-weight" from "Overweight" as the stock’s recent strong performance leaves limited near-term upside, despite continued business ...
SchaeffersResearch.com4d
Hims and Hers Stock Drops Weight as Earnings Loom
Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...
Piper Sandler Keeps Their Hold Rating on Hims & Hers Health (HIMS)
In a report released today, Korinne Wolfmeyer from Piper Sandler maintained a Hold rating on Hims & Hers Health (HIMS – Research Report), ...
Seeking Alpha7d
Hims & Hers downgraded at Morgan Stanley on recent rally
Morgan Stanley downgraded telehealth firm Hims & Hers Health (NYSE:HIMS) to Equal Weight from Overweight on Tuesday ahead of its Q4 2024 results next week, citing the stock’s recent rally.
Hims & Hers Health (NYSE:HIMS) Downgraded by Morgan Stanley to Equal Weight
Morgan Stanley cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from an overweight rating to an equal weight rating ...
Benzinga.com1d
Smart Money Is Betting Big In HIMS Options
Click here for access. * Maintaining their stance, an analyst from B of A Securities continues to hold a Underperform rating for Hims & Hers Health, targeting a price of $21. * In a cautious move, ...